On track to submit GraftAssureDx™ for FDA review by year-endOn track for commitment to have 20 transplant centers globally ...
StandardAero (NYSE: SARO) announced results today for the three months ended September 30, 2025 ("Third Quarter 2025").
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
Research and development expenses for the third quarter of 2025 were $14.0 million, compared with $11.6 million for the third quarter in 2024. The increase was primarily due to additional costs ...
The third trial in the PIONEER program, PIONEER-3, will evaluate Privosegtor after the acute onset of NAION. This study shares the core design and operational elements with PIONEER-1 and PIONEER-2 and ...
Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia set to launch in NovemberTonmya is the first new FDA-approved ...
Out of the 875 Sikorsky S-76 helicopters that have been produced till date, approximately 284 were of the S-76A type - the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback